Asset Details
Do you wish to reserve the book?
Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
Do you wish to request the book?
Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
2012
Overview
In a study of patients with Alzheimer's disease and associated psychosis or agitation that had responded to risperidone, the risk of relapse was greater among patients randomly assigned to switch to placebo than among those who continued to receive risperidone.
Symptoms of psychosis or agitation are common in Alzheimer's disease.
1
,
2
These symptoms are associated with distress on the part of the patient, an increased burden on caregivers, more rapid cognitive decline, an increased likelihood of institutionalization, and increased health care costs.
3
Nonpharmacologic behavioral treatment approaches may help,
4
–
9
but large, controlled trials are needed to confirm the effectiveness of these strategies.
Among psychotropic medications, only antipsychotic agents show superiority over placebo for the treatment of psychosis and agitation–aggression in patients with dementia, although they are associated with only low-to-moderate efficacy.
10
–
12
Side effects of antipsychotic drugs include sedation, extrapyramidal . . .
Publisher
Massachusetts Medical Society
Subject
Adult and adolescent clinical studies
/ Aged
/ Alzheimer Disease - drug therapy
/ Alzheimer Disease - psychology
/ Antipsychotic Agents - adverse effects
/ Antipsychotic Agents - therapeutic use
/ Biological and medical sciences
/ Dementia
/ Female
/ Humans
/ Male
/ Organic mental disorders. Neuropsychology
/ Patients
/ Psychology. Psychoanalysis. Psychiatry
/ Psychomotor Agitation - complications
/ Psychomotor Agitation - drug therapy
/ Psychotic Disorders - complications
/ Psychotic Disorders - drug therapy
/ Risk
/ Risperidone - adverse effects
